Navin Fluorine to host Analyst/Investor Meet on Feb 18, 2026
Navin Fluorine will host an analyst and investor meet on February 18, 2026. The company reported Q3 FY26 consolidated sales of ₹892.4 crore (up 47% YoY) and Operating EBITDA of ₹307.6 crore (up 109% YoY). For 9M FY26, sales were ₹2,376.2 crore (up 44% YoY) and EBITDA was ₹760.5 crore (up 114% YoY).
The strong financial performance, coupled with upcoming investor interactions and ongoing strategic capex, suggests a positive outlook and significant developments for the company, impacting investor sentiment and potentially its stock.
The announcement includes strong financial results with significant year-on-year growth in sales and EBITDA, alongside an upcoming investor interaction, indicating positive performance and proactive stakeholder engagement.
Navin Fluorine International Limited has announced that officials from the company will be interacting with Analysts and Investors on February 18, 2026, at 13:00 PM IST. The discussions will be based on publicly available information, and a presentation will be shared during the meeting.
The company also reported strong financial performance for Q3 and 9M FY26. Consolidated sales for Q3 FY26 were ₹892.4 crore, a 47% year-on-year increase, with Operating EBITDA at ₹307.6 crore, up 109% year-on-year. For the 9M FY26 period, consolidated sales reached ₹2,376.2 crore, a 44% increase year-on-year, and Operating EBITDA was ₹760.5 crore, up 114% year-on-year.
Significant capital expenditure projects are underway, including an additional HFC capacity expected to be commissioned by Q3FY27, and de-bottlenecking of MPP capacity at Dahej targeted for Q3FY27. An advanced materials project is slated for commissioning by Q1FY27.
The company highlighted its diversified business model across Specialty Chemicals, HPP, and CDMO segments, with strong growth drivers including constructive global demand for low GWP gases and increasing demand for RAC and blends in India and export markets. The Specialty Chemicals segment saw a 60% revenue growth, driven by a strong product pipeline and new molecule launches. The CDMO business continued its momentum with a 61% revenue growth, supported by strong order visibility and successful completion of validation for a European CDMO MSA.
What to do with a filing like this
Navin Fluorine International Limited filed this with the NSE as a statutory disclosure, categorised under investor meet intimation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Navin Fluorine International Limited. Read the original for the full detail.